Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma

Overview of attention for article published in Frontiers in oncology, August 2022

Altmetric Badge

Mentioned by

twitter: 2 X users

Readers on

mendeley: 6 Mendeley

So far, Altmetric has seen 2 X posts from 2 X users, with an upper bound of 18,558 followers.

Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by chemoradiotherapy in patients with Stage III squamous cell anal carcinoma https://t.co/dKCxpGSHA7 https://t.co/y3kJBhyPyc

08 Nov 2022

Reply Repost Favourite

RT @FrontOncology: 📄 Phase II INTERACT-ION study: ezabenlimab (BI 754091) and mDCF (docetaxel, cisplatin, and 5-fluorouracil) followed by #…

06 Nov 2022

Reply Repost Favourite

This page shows the most recent X posts that mention this research output.

Click here to find out how to access more activity.